In addition, SLAP silencing increases intestinal tumour initiation and progression in ApcΔ14/+ transgenic mice that carry a heterozygous mutation of the APC tumour-suppressor gene and consequently develop WNT-pathway-driven intestinal tumours. The gene discussed is SLA; the disease is intestinal neoplasm.